Table 6 Migraine costs (population estimates)
|  | Luxembourg N = 124,713 | Russia N = 18,122,512 | Spain N = 10,772,263 | |||
|---|---|---|---|---|---|---|
Cost (euros) 1-year estimate | Cost (euros) 5-year estimate | Cost (euros) 1-year estimate | Cost (euros) 5-year estimate | Cost (euros) 1-year estimate | Cost (euros) 5-year estimate | |
CURRENT CARE: NO CONSUMER EDUCATION OR HEALTH-CARE PROFESSIONAL TRAINING | ||||||
 Primary analysis | ||||||
  Medications | ||||||
   acute non-specific ASA 1 g | 7568 | 35,364 | 855,296 | 3,996,867 | 508,399 | 2,375,791 |
   acute-specific sumatriptan 50 mg | 3635 | 16,986 | 1,207,420 | 5,642,371 | 251,626 | 1,175,870 |
   prophylaxis amitriptyline 100 mg/day | 695 | 3249 | 195,304 | 912,670 | 20,816 | 97,276 |
   Total medications | 11,898 | 55,599 | 2,258,020 | 10,551,908 | 780,841 | 3,648,937 |
  Health-care provision | ||||||
   GP visits | 1,868,796 | 6,153,787 | 133,597,931 | 493,496,811 | 185,508,849 | 725,403,433 |
   specialist visits | 708,809 | 708,809 | 126,073,602 | 126,073,602 | 125,445,228 | 125,445,229 |
   MRI | 361,613 | 361,613 | 77,008,823 | 77,008,823 | 73,240,116 | 73,240,116 |
   Total health-care provision | 2,939,218 | 7,224,209 | 336,680,356 | 696,579,236 | 384,194,193 | 924,088,778 |
  Secondary analyses | ||||||
   Total lost productivity | 120,885,706 | 564,908,477 | 2,045,525,786 | 9,558,904,021 | 4,136,426,354 | 19,329,847,995 |
   Sensitivity analysis: disability accounts for 20% lost productivity | 24,177,141 | 112,981,695 | 409,105,157 | 1,911,780,804 | 827,285,271 | 3,865,969,599 |
TARGET CARE: WITH CONSUMER EDUCATION AND HEALTH-CARE PROFESSIONAL TRAINING | ||||||
 Primary analysis | ||||||
  Medications | ||||||
   acute non-specific ASA 1 g | 16,564 | 77,405 | 1,498,933 | 7,004,632 | 370,931 | 1,733,392 |
   acute-specific sumatriptan 50 mg | 153,854 | 718,974 | 50,269,478 | 234,913,251 | 10,313,113 | 48,193,995 |
   prophylaxis amitriptyline 100 mg/day | 30,050 | 140,425 | 7,857,564 | 36,719,020 | 899,802 | 4,204,845 |
   Total medications | 200,468 | 936,804 | 59,625,975 | 278,636,903 | 11,583,846 | 54,132,232 |
  Health-care provision | ||||||
  GP visits | 4,357,297 | 12,893,134 | 373,410,366 | 1,104,912,154 | 399,420,967 | 1,181,876,886 |
  specialist visits | 611,042 | 611,042 | 74,160,942 | 74,160,942 | 46,119,569 | 46,119,569 |
   MRI | 62,347 | 62,347 | 9,059,861 | 9,059,861 | 5,385,303 | 5,385,303 |
  Total health-care provision | 5,030,686 | 13,566,523 | 456,631,169 | 1,188,132,957 | 450,925,839 | 1,233,381,758 |
 Secondary analyses | ||||||
  Total lost productivity | 5,431,622 | 373,419,228 | 1,296,237,360 | 6,057,419,858 | 2,621,228,447 | 12,249,208,158 |
  Sensitivity analysis: disability accounts for 20% lost productivity | 1,086,324 | 74,683,846 | 259,247,472 | 1,211,483,972 | 524,245,689 | 2,449,841,632 |